Prima BioMed (NASDAQ:IMMP – Get Free Report) will likely be issuing its H2 2026 results before the market opens on Wednesday, September 2nd. Analysts expect the company to post earnings of ($0.0258) per share and revenue of $11.7250 million for the quarter. Investors may review the information on the company’s upcoming H2 2026 earning summary page for the latest details on the call scheduled for Sunday, August 30, 2026 at 6:00 PM ET.
Prima BioMed Price Performance
Shares of NASDAQ IMMP opened at $0.38 on Monday. Prima BioMed has a 1-year low of $0.29 and a 1-year high of $3.53. The stock’s 50-day moving average is $0.40 and its 200 day moving average is $0.80.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on IMMP shares. Maxim Group upgraded Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Prima BioMed in a report on Friday, July 10th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $5.50.
Institutional Inflows and Outflows
An institutional investor recently raised its stake in Prima BioMed stock. Jane Street Group LLC grew its position in shares of Prima BioMed Ltd (NASDAQ:IMMP – Free Report) by 14.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 51,574 shares of the biotechnology company’s stock after buying an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 2.32% of the company’s stock.
Prima BioMed Company Profile
Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.
See Also
- Five stocks we like better than Prima BioMed
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Prima BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
